Hims & Hers Health is trading at €23.90 (-4.93%) after the FDA highlighted more than 1,700 adverse-event reports involving compounded semaglutide and tirzepatide.
- The alert cited dosing errors, contamination, poor refrigeration, fraudulent labeling, and questionable ingredients.
- The findings renewed concerns about compounded GLP-1 products.
- The decline occurred despite broader U.S. equities advancing on September 3, 2026.